. | Age at onset . | HLA susceptibility . | Autoimmunity (autoantibodies) . | Ketosis . | BMI . | Insulin secretion . | Metabolic syndrome . | Insulin resistance . | Initial therapy . |
---|---|---|---|---|---|---|---|---|---|
Type 1 | |||||||||
diabetes | Young/adult | Yes (strong) | Yes (strong) | Present | Normal | Absent/low | Infrequent | Absent/infrequent | Insulin |
LADA | Adult | Yes | Yes (by definition) | Absent | Normal/high | Present (but declines) | Variable | Variable | Insulin/OHA* |
Type 2 diabetes | Adult | No | No | Absent | High | Present | Frequent | Present | LSO/OHA |
. | Age at onset . | HLA susceptibility . | Autoimmunity (autoantibodies) . | Ketosis . | BMI . | Insulin secretion . | Metabolic syndrome . | Insulin resistance . | Initial therapy . |
---|---|---|---|---|---|---|---|---|---|
Type 1 | |||||||||
diabetes | Young/adult | Yes (strong) | Yes (strong) | Present | Normal | Absent/low | Infrequent | Absent/infrequent | Insulin |
LADA | Adult | Yes | Yes (by definition) | Absent | Normal/high | Present (but declines) | Variable | Variable | Insulin/OHA* |
Type 2 diabetes | Adult | No | No | Absent | High | Present | Frequent | Present | LSO/OHA |
LSO, lifestyle optimization; OHA, oral hypoglycemic agents.
*Preferable that sulfonylureas are not chosen as first-line therapy.